CLINICAL TRIALS PROFILE FOR SEVENFACT
✉ Email this page to a colleague
All Clinical Trials for SEVENFACT
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT04563520 ↗ | SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis | Not yet recruiting | Takeda Pharmaceuticals North America, Inc. | Phase 3 | 2021-12-01 | The purpose of the aPCC-emicizumab safety study is to prospectively investigate the safety and hemostatic efficacy of a personalized dose of aPCC in children and adults with hemophilia A and inhibitors on emicizumab prophylaxis during acute bleeding events or prior to procedures. |
| NCT04563520 ↗ | SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis | Not yet recruiting | Emory University | Phase 3 | 2021-12-01 | The purpose of the aPCC-emicizumab safety study is to prospectively investigate the safety and hemostatic efficacy of a personalized dose of aPCC in children and adults with hemophilia A and inhibitors on emicizumab prophylaxis during acute bleeding events or prior to procedures. |
| NCT04647227 ↗ | SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors | Recruiting | LFB USA, Inc. | Phase 4 | 2021-06-28 | Phase IV multi-center, US-centric, open-label, safety study enrolling participants with Hemophilia A or B with inhibitors aged 12 to 65 years, inclusive, who are either on long term prophylactic treatment (e.g., emicizumab) at risk of experiencing a breakthrough bleeding event (BE), or who are not on prophylactic treatment who may need to control a BE. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SEVENFACT
Condition Name
Clinical Trial Locations for SEVENFACT
Trials by Country
Clinical Trial Progress for SEVENFACT
Clinical Trial Phase
Clinical Trial Sponsors for SEVENFACT
Sponsor Name
